主页 > 医药生命 >
【medical-news】Prognostic Enzyme For Nasopharyngeal Cancer
Main Category: Cancer / Oncology News
Article Date: 22 Apr 2007 - 7:00 PDT
| email this article | printer friendly | view or write opinions |
Mayo Clinic Cancer Center scientists, in collaboration with Chinese researchers, have isolated an enzyme that could be used to predict survival and recurrence rates for nasopharyngeal cancer -- a common cancer affecting people from Southeast Asia. Results of the study were presented by lead author Jin-Ping Lai, M.D., Ph.D., at the American Association for Cancer Research annual meeting.
Nasopharyngeal cancer disproportionately affects people living in southern China and surrounding areas, as well as recent Southeast Asian immigrants to the United States, says the American Cancer Society. It also is common in Alaska Natives and is 50 percent more likely to occur in blacks than in whites.
SULF2, a recently identified heparin-degrading endosulfatase, appears to be significantly overexpressed in nasopharyngeal cancers, providing hope of the eventual ability to predict recurrence and subsequent prognosis after radiation therapy, the standard treatment for nasopharyngeal cancer.
The researchers examined tumor tissue from 55 patients with squamous cell carcinoma of the nasopharynx, otherwise known as nasopharyngeal cancer. All patients had been treated by radiation therapy and follow-up was conducted for 10 years. The investigators found that rates of early recurrence (within five years) were significantly higher for individuals with high levels of SULF2 in the tumor (expressed in more than 10 percent of cancer cells). These same individuals were much more likely to die within 10 years.
"Learning more about the way a specific type of cancer develops, and what proteins it produces as it grows, helps us find better ways to treat that cancer," said Dr. Lai, who is a cancer researcher at Mayo Clinic with background as an otolaryngologist. "With nasopharyngeal cancer, we think this new enzyme may help solve the puzzle."
Locating the enzyme also allowed Dr. Lai and his colleagues to make the antibody for SULF2, which is a step leading to an effective treatment for nasopharyngeal cancer. SULF2 also appears to be a factor in liver cancer, a link under investigation by the Mayo researchers.
"We continue to look for ways to combat health disparities in the United States and throughout the world," said Lewis Roberts, M.B.Ch.B., Ph.D., the study's principal investigator and a gastroenterologist at Mayo Clinic. "Our research into SULF2 suggests a number of promising possibilities for the development of more effective treatments for cancer."
http://www.medicalnewstoday.com/medicalnews.php?newsid=68163 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Prognostic Enzyme For Nasopharyngeal Cancer Identified
对已确诊的鼻咽癌具有预后作用的酶
Main Category: Cancer / Oncology News
Article Date: 22 Apr 2007 - 7:00 PDT
| email this article | printer friendly | view or write opinions |
Mayo Clinic Cancer Center scientists, in collaboration with Chinese researchers, have isolated an enzyme that could be used to predict survival and recurrence rates for nasopharyngeal cancer -- a common cancer affecting people from Southeast Asia. Results of the study were presented by lead author Jin-Ping Lai, M.D., Ph.D., at the American Association for Cancer Research annual meeting.
Mayo临床肿瘤中心的科学家，通过与中国科研工作者合作，目前分离出了一种酶，该酶可以用来预测鼻咽癌的生存和复发率。鼻咽癌是东南亚常见的一种肿瘤。该研究成果，由第一作者Jin-Ping Lai医学博士在美国协会主办的肿瘤研究年会上公布。
Nasopharyngeal cancer disproportionately affects people living in southern China and surrounding areas, as well as recent Southeast Asian immigrants to the United States, says the American Cancer Society. It also is common in Alaska Natives and is 50 percent more likely to occur in blacks than in whites.
美国癌症协会称，鼻咽癌特发于居住于中国南部及其周围的地区的人，包括最近移居美国的东南亚移民。在阿拉斯加原住民中也很常见，与白人相比，黑人中的发病率大约要高出50%以上。
SULF2, a recently identified heparin-degrading endosulfatase, appears to be significantly overexpressed in nasopharyngeal cancers, providing hope of the eventual ability to predict recurrence and subsequent prognosis after radiation therapy, the standard treatment for nasopharyngeal cancer.
SULF2，最近确认的肝素降解内源性硫酸酯酶，在鼻咽癌中明显高表达。从而为在经过标准鼻咽癌治疗—放疗治疗后，预测复发和后续诊断的可能带来了希望。
The researchers examined tumor tissue from 55 patients with squamous cell carcinoma of the nasopharynx, otherwise known as nasopharyngeal cancer. All patients had been treated by radiation therapy and follow-up was conducted for 10 years. The investigators found that rates of early recurrence (within five years) were significantly higher for individuals with high levels of SULF2 in the tumor (expressed in more than 10 percent of cancer cells). These same individuals were much more likely to die within 10 years.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-11-06 05:11
医学,生命科学网